PL1661890T3 - Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek - Google Patents
Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związekInfo
- Publication number
- PL1661890T3 PL1661890T3 PL04772699T PL04772699T PL1661890T3 PL 1661890 T3 PL1661890 T3 PL 1661890T3 PL 04772699 T PL04772699 T PL 04772699T PL 04772699 T PL04772699 T PL 04772699T PL 1661890 T3 PL1661890 T3 PL 1661890T3
- Authority
- PL
- Poland
- Prior art keywords
- ppar
- pharmaceutical composition
- composition containing
- containing same
- activating compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
| EP04772699A EP1661890B1 (en) | 2003-09-03 | 2004-09-02 | Ppar-activating compound and pharmaceutical composition containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1661890T3 true PL1661890T3 (pl) | 2011-06-30 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04772699T PL1661890T3 (pl) | 2003-09-03 | 2004-09-02 | Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (pl) |
| EP (1) | EP1661890B1 (pl) |
| JP (2) | JP4226005B2 (pl) |
| KR (1) | KR101160808B1 (pl) |
| AU (1) | AU2004270538C1 (pl) |
| BR (1) | BRPI0413991B8 (pl) |
| CA (1) | CA2535749C (pl) |
| CY (1) | CY1111867T1 (pl) |
| EA (1) | EA009374B1 (pl) |
| HR (1) | HRP20110009T1 (pl) |
| IL (1) | IL173639A (pl) |
| MX (1) | MXPA06002435A (pl) |
| NO (1) | NO335823B1 (pl) |
| NZ (1) | NZ545692A (pl) |
| PL (1) | PL1661890T3 (pl) |
| TW (1) | TWI324599B (pl) |
| WO (1) | WO2005023777A1 (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE457995T1 (de) | 2003-06-18 | 2010-03-15 | Tranzyme Pharma Inc | Makrozyklische motilin rezeptorantagonisten |
| JP4928262B2 (ja) * | 2003-07-31 | 2012-05-09 | トランザイム・ファーマ | 薬物発見に有用な空間的に規定された大環状化合物 |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| DK1852426T3 (da) * | 2005-02-23 | 2013-11-25 | Kowa Co | Fremgangsmåde til fremstilling af en optisk aktiv ppar-aktiverende forbindelse og mellemprodukt af samme |
| US7538242B2 (en) | 2005-03-01 | 2009-05-26 | Kowa Co., Ltd. | Optically active PPAR-activating compound intermediate and method for producing same |
| DE602006013815D1 (de) * | 2005-05-31 | 2010-06-02 | Kowa Co | Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung |
| WO2007013555A1 (ja) | 2005-07-28 | 2007-02-01 | Kowa Co., Ltd. | 光学活性２－ヒドロキシ酪酸エステルの製造法 |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| EP2484361B1 (en) | 2009-09-28 | 2015-11-11 | Kowa Company, Ltd. | Agent for reducing visceral fat weight |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | 優生生物科技股份有限公司 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases |
| BR112015006305B1 (pt) | 2012-09-27 | 2020-11-17 | Kowa Company, Ltd. | composições farmacêuticas para prevenir e/ou tratar dislipidemia e para aumentar o colesterol de hdl |
| CN105102415B (zh) | 2013-03-29 | 2017-03-15 | 兴和株式会社 | 2‑羟基羧酸或其衍生物的光学纯度提高法 |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| EP3040071A4 (en) | 2013-08-28 | 2017-04-12 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| AU2015204572B2 (en) * | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| WO2017082393A1 (ja) * | 2015-11-12 | 2017-05-18 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| SI3275438T1 (sl) | 2016-07-29 | 2021-05-31 | Kowa Company, Ltd. | Metode preprečevanja kardiovaskularnih dogodkov pri dislipidemični populaciji z rezidualnim tveganjem |
| CA3032630C (en) * | 2016-08-25 | 2022-10-11 | Kowa Company, Ltd. | Agent for treatment of pbc |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| AU2018206907B2 (en) | 2017-01-11 | 2023-11-02 | Kowa Company, Ltd. | Prophylactic and therapeutic drug for nonalcoholic fatty liver disease |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| US20200129483A1 (en) | 2017-06-30 | 2020-04-30 | Kowa Company, Ltd. | Pharmaceutical composition |
| US11419855B2 (en) | 2017-06-30 | 2022-08-23 | Kowa Company, Ltd. | Pharmaceutical preparation |
| US20200113873A1 (en) | 2017-06-30 | 2020-04-16 | Kowa Company, Ltd. | Medicament |
| US11344535B2 (en) * | 2017-06-30 | 2022-05-31 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| KR102512518B1 (ko) | 2017-06-30 | 2023-03-21 | 교와 가부시키가이샤 | 페마피브레이트를 함유하는 의약 |
| WO2019004448A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| HRP20241476T1 (hr) * | 2017-06-30 | 2025-01-03 | Kowa Company, Ltd. | Farmaceutski pripravak |
| US11298340B2 (en) | 2017-06-30 | 2022-04-12 | Kowa Company, Ltd. | Pharmaceutical composition |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| JP2021504315A (ja) | 2017-11-21 | 2021-02-15 | ルジェニクス，インコーポレーテッド | 多形及びその使用 |
| SG11202005850VA (en) * | 2017-12-21 | 2020-07-29 | Kowa Co | Methods of treatment of hypertrigl yceridemia |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| US11420945B2 (en) | 2017-12-27 | 2022-08-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of Pemafibrate |
| WO2019216313A1 (ja) | 2018-05-08 | 2019-11-14 | 国立大学法人岡山大学 | 心血管疾患に有用な医薬 |
| EP3903781A4 (en) | 2018-12-27 | 2023-01-25 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
| WO2020138407A1 (ja) * | 2018-12-27 | 2020-07-02 | 興和株式会社 | 医薬品 |
| TWI829840B (zh) | 2018-12-27 | 2024-01-21 | 日商興和股份有限公司 | 醫藥組成物 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
| BR112023021643A2 (pt) | 2021-04-20 | 2023-12-19 | Kowa Co | Composição farmacêutica para prevenir e/ou tratar dislipidemia ou doença cardiovascular |
| WO2022230920A1 (ja) | 2021-04-28 | 2022-11-03 | 興和株式会社 | 血中カルニチン増加剤 |
| AU2023244808A1 (en) | 2022-03-31 | 2024-09-26 | Kowa Company, Ltd. | Therapeutic agent for respiratory disease |
| TW202408499A (zh) | 2022-07-06 | 2024-03-01 | 日商興和股份有限公司 | 降低血中肌肉生長抑制素之藥劑 |
| EP4556006A4 (en) | 2022-07-15 | 2026-01-07 | Kowa Co | MEDICATION TO LOWER LDL CHOLESTEROL IN THE BLOOD |
| WO2024201358A1 (en) * | 2023-03-31 | 2024-10-03 | Ami Lifesciences Private Limited | A process for the preparation of pemafibrate and intermediates thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| JPWO2002046176A1 (ja) * | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体の活性化剤 |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| US7319104B2 (en) * | 2002-03-01 | 2008-01-15 | Smithkline Beecham Corporation | hPPARs activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko not_active Expired - Fee Related
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja not_active Expired - Lifetime
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja not_active Ceased
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx not_active IP Right Cessation
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en not_active Expired - Lifetime
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en not_active Expired - Lifetime
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173639A0 (en) | Ppar-activating compound and pharmaceutical composition containing same | |
| IL174128A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL197889A (en) | Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same | |
| IL173602A0 (en) | Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same | |
| IL173627A0 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same | |
| IL164455A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL173051A0 (en) | N-glucoside derivatives and pharmaceutical compositions containing the same | |
| IL171997A0 (en) | Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| IL175214A0 (en) | 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same | |
| IL165388A0 (en) | Macrolide compounds and pharmaceutical compositions containing the same | |
| IL164547A0 (en) | Pharmaceutical composition | |
| IL172159A0 (en) | 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same | |
| GB0300427D0 (en) | Pharmaceutical composition | |
| IL165878A0 (en) | Pharmaceutical composition | |
| IL174249A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| GB0307866D0 (en) | Pharmaceutical composition | |
| EP1699458A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0317663D0 (en) | Pharmaceutical composition | |
| IL176077A0 (en) | 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them | |
| GB0300885D0 (en) | Pharmaceutical composition | |
| GB0306933D0 (en) | Pharmaceutical composition | |
| ZA200601232B (en) | 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them | |
| GB0307869D0 (en) | Pharmaceutical composition | |
| GB0307867D0 (en) | Pharmaceutical composition |